An observational study in Diabetes, Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Malaysia. Per ClinicalTrials.gov, last updated 2016-11-22.
Sponsored by Novo Nordisk A/S · Observational
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control, and complications in diabetic subjects in Asia.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 1,670 is above the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Novo Nordisk A/S is the lead sponsor of 1,370 studies on the registry; 101 are open to participants now.
Of its 198 completed or terminated interventional studies of FDA-regulated products, 94 (47%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with diabetes mellitus (both type 1 and type 2) being treated at general hospitals, diabetes clinics and referral clinics will be selected according to the inclusion and exclusion criteria.
Exclusion Criteria:
Other: No treatment given
Subject will only fill out a questionaire when entering the observational study.
Mean age of onset of type 1 and type 2 diabetes mellitus, respectively
Time frame: at baseline visit/study start
Mean duration of treatment of type 2 Diabetes mellitus
Time frame: at baseline visit/study start
Percentage of patients on insulin and Oral Anti-Diabetics Drugs (OADs) theraphy, respectively
Time frame: at baseline visit/study start
Mean duration of diabetes in type 1 and type 2 diabetic patients respectively
Time frame: at baseline visit/study start
Mean FPG (Fasting plasma glucose), PPG (Post prandial glucose) and HbA1c of diabetic patients
Time frame: at baseline visit/study start
Percentage of diabetic patients with HbA1c target below 7.0% and below 6.5%, respectively
Time frame: at baseline visit/study start
Percentage of diabetic patients having dyslipidemia and hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy and diabetic eye complications, respectively
Time frame: at baseline visit/study start
Patients' perception will be analysed through patient questionnaire measuring: Psychological well-being, Quality of Life and patients' compliant to treatmen
Time frame: at baseline visit/study start
Physician perception of diabetes and its management will be analysed through physician questionnaire measuring awareness about: HbA1c test and its goal, anti-diabetic treatment, barriers towards optimum diabetes control
Time frame: at baseline visit/study start
Duration of diabetes associated with highest number of diabetic complications
Time frame: at baseline visit/study start
Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy)
Time frame: at baseline visit/study start
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novo Nordisk A/S